Enrotron 5 mg/ml oral solution for pigs

国: アイルランド

言語: 英語

ソース: HPRA (Health Products Regulatory Authority)

有効成分:

Enrofloxacin

から入手可能:

aniMedica GmbH

ATCコード:

QJ01MA90

INN（国際名）:

Enrofloxacin

投薬量:

5 milligram(s)/millilitre

医薬品形態:

Oral solution

処方タイプ:

POM: Prescription Only Medicine as defined in relevant national legislation

治療群:

Pigs

治療領域:

enrofloxacin

適応症:

Antibacterial

認証ステータス:

Authorised

承認日:

2013-06-21

製品の特徴

Health Products Regulatory Authority
22 August 2018
CRN008DKX
Page 1 of 5
SUMMARY OF PRODUCT CHARACTERISTICS
1 NAME OF THE VETERINARY MEDICINAL PRODUCT
Enrotron 5 mg/ml oral solution for pigs
2 QUALITATIVE AND QUANTITATIVE COMPOSITION
1 ml contains:
ACTIVE SUBSTANCE:
Enrofloxacin 5.0 mg
EXCIPIENTS:
Benzyl alcohol (E-1519) 14.0 mg
For the full list of excipients, see section 6.1.
3 PHARMACEUTICAL FORM
Oral solution
Clear slightly yellow solution.
4 CLINICAL PARTICULARS
4.1 TARGET SPECIES
Pigs (piglets)
4.2 INDICATIONS FOR USE, SPECIFYING THE TARGET SPECIES
Treatment of infections of the respiratory and alimentary tract caused
by
enrofloxacin-sensitive microorganisms. In particular:

Treatment of neonatal diarrhoea and septicaemia caused by
enrofloxacin-sensitive _E. coli_

Treatment of respiratory infections caused by enrofloxacin-sensitive
_Pasteurella multocida_, _Mannheimia haemolytica_ and _Mycoplasma
_spp.

Enzootic pneumonia
To be used where clinical experience and/or sensitivity testing
indicates enrofloxacin
as the drug of choice.
Health Products Regulatory Authority
22 August 2018
CRN008DKX
Page 2 of 5
4.3 CONTRAINDICATIONS
Do not use in cases of hypersensitivity to the active substance, to
other
(fluoro)quinolones or to any of the excipients.
Do not use in cases of disturbances to the growth of cartilage and/or
during injury to
the locomotory system, particularly if functionally loaded or body
weight loaded
joints are affected.
4.4 SPECIAL WARNINGS FOR EACH TARGET SPECIES
None.
4.5 SPECIAL PRECAUTIONS FOR USE
Special precautions for use in animals
Official and local antimicrobial policies should be taken into account
when the
product is used.
Do not use in case of confirmed or suspected resistance to quinolones,
since a high
degree of cross resistance between enrofloxacin and other quinolones
does exist.
Fluoroquinolones should be reserved for the treatment of clinical
conditions which
have responded poorly, or are expected to respond poorly, to other
classes of
antimicrobials.
Susceptibility te